Abcam, ab226150, Anti-XRCC1 antibody [EPR4389(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal XRCC1 antibody. Carrier free. Suitable for ICC/IF, WB and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR4389(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat, Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab226150 is the carrier-free version of
ab134056
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
XRCC1 (X-ray repair cross-complementing protein 1) plays a role in DNA repair by acting as a scaffold protein. It weighs approximately 70 kDa and is expressed in various tissues reflecting its role in maintaining genomic stability. XRCC1 helps in the repair of single-strand breaks by coordinating the activity of several enzymes involved in the base excision repair pathway. Together with other proteins it helps ensure the integrity of DNA by fostering repair mechanisms following damage by ionizing radiation or other environmental factors.
Biological function summary
The activity of XRCC1 integrates into DNA damage response as it partners with enzymes like DNA ligase III DNA polymerase beta and poly (ADP-ribose) polymerase (PARP). This protein functions by forming complexes with these enzymes facilitating quick and accurate repair. The ability of XRCC1 to bring together repair machinery is essential for cell survival after DNA damage and plays a role in the prevention of mutagenesis and carcinogenesis as errors in repair processes could lead to genetic mutations.
Pathways
The XRCC1 protein participates in base excision repair and single-strand break repair pathways. It works closely with PARP1 and DNA ligase III to correct single-strand DNA interruptions. Through these pathways XRCC1 interacts with other repair proteins like TDP1 aiding in the resolution of complex DNA end structures. This collaboration ensures the completion of cellular repair processes maintaining genomic integrity and reducing the likelihood of accumulating harmful mutations.
Mutations in XRCC1 have links to cancer development particularly those involving increased susceptibility to tobacco-related cancers. Studies have connected XRCC1 polymorphisms to a higher risk for conditions such as breast and lung cancer. Relations between XRCC1 and disorders can also be observed with neurodegenerative conditions; for instance alterations in its function or expression patterns might amplify disease progression involving neurological decline. Moreover its interactions with proteins like PARP1 bring forth potential implications in therapeutic strategies aiming to exploit DNA repair pathways for targeted cancer treatments.